| Prev Close | 6.60 |
| Day Low/High | 6.46 / 6.84 |
| 52 Wk Low/High | 3.26 / 8.87 |
Viking Therapeutics, Inc. (VKTX)
6.84
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 72.76B |
| Market Cap | 480.21M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
The Best Approach to Trading Lyft
Valuation and all the other issues that are being discussed are secondary to the price action.
Is This Market Action Foreshadowing Something Worse?
This trading is starting to create some fairly deep pullbacks.
The Market Close Will Tell Us a Lot About Momentum
Sharp intraday reversals tend to lead to more selling.
The Market Is Transitioning Back to Stock Picking
There are obvious signs that people are trying to put cash to work.
Quiet Trading Allowing Some Biotech Names to Perk Up
After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.
Viking Therapeutics Shows How Quickly This Market Can Turn
If you are trying to pick stocks for the longer term it can be quite challenging right now.
This Is Not Just a Market of Oversold Bounces Now
What is most interesting about the action today is a spike in the speculative action.
My Stock of the Week: ENDRA Life Sciences
I'm simply focusing on individual stocks at this point and am not too concerned about the macro picture.
It Was a Very Rough Week
Just when you thought the worst was over another wave of selling would hit.
Is the Market Washed Out and Ready for Another Upcycle?
One very encouraging sign Friday is relative outperformance by names that have lately been the weakest.
CAT Stock Gets Thrown Into the Dumpster
This stock can become much cheaper if there is a major cycle turn occurring.
6 Steps for Dealing With a Market That Can't Be Trusted
They include holding a high level of cash, keeping stops tight and being patient.
Netflix Is Tonight's Big Report: Here's How I Would Play It
This is a battleground stock that has made big moves in both directions on earnings in the past.
Square Continues to See Extreme Pressure
If you are interested in Square longer term be patient and wait for the drama to end.
There's Nothing Very Attractive About GE
It's an interesting story but there are better places for your funds.
FedEx's Report Was Soft, but the Guidance Isn't Bad
It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.
Six Biotechnology Names on My Watch List
After recent weakness in the biotech sector, here are some names to start watching.
A Lesson to Learn From Thursday's Market Action
You don't have to be Sigmund Freud to understand the psychology here.
Overall the Market Is in Good Shape
The action started a little slowly this morning but market players shook off early jitters and are doing a nice job of building on yesterday's momentum.
There Is Still a Strong Appetite for Big Moving Speculative Names
There isn't any big mystery about what is going on here.
Sound Familiar? Dovish Fed Talk Induces Stock Reversal
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Choppy Market Action This Morning
The good news is that there is some stock picking that is working well.
How Unusual This Market Action Is
Despite this huge move over the last five days the indices still have more work to do to make it back to highs.
Traders Need to Adapt to a New Reality
The volatility trade that propped up markets is no longer available.
The Confidence in the Dip Buyers Has Weakened
The bears are likely to be increasingly bold if there's a failed bounce.
This 'Correction' May Turn Out to Be Another Dud
Once the dip buying starts it becomes self-reinforcing.
The Nature of Markets
The best thing you can do right now is work on shopping lists of potential buys.
Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk
Interest and volume in the stock picked up in September and continues to build.